# Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs

Study · id `cardio:ct-nct04980027` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04980027](<https://clinicaltrials.gov/study/NCT04980027>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04980027

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 228 participants.

## Technical summary

Registry record NCT04980027. Allocation not applicable; no masking; primary purpose treatment. Start 2021-06-07 (actual); primary completion 2022-12-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 228 participants (enrolled count; ClinicalTrials.gov record NCT04980027, source copy `cardio:ctgov-nct04980027-2025-09-22`, retrieved 2026-10-26)
- Started: 2021-06-07 (actual) (ClinicalTrials.gov record NCT04980027, source copy `cardio:ctgov-nct04980027-2025-09-22`, retrieved 2026-10-26)
- Primary completion: 2022-12-23 (actual) (ClinicalTrials.gov record NCT04980027, source copy `cardio:ctgov-nct04980027-2025-09-22`, retrieved 2026-10-26)
- Completion: 2022-12-23 (actual) (ClinicalTrials.gov record NCT04980027, source copy `cardio:ctgov-nct04980027-2025-09-22`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT04980027, source copy `cardio:ctgov-nct04980027-2025-09-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04980027-2025-09-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs
- Acronym: SAFEGUARD
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin glargine (U300)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 8f78cffd62d446506ce4a910b15d67ad4596ccda156ab30db586ac4158cd153d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
